Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biovie Inc

Healthcare US BIVI

1.92USD
0.16(9.09%)

Last update at 2026-06-22T17:51:00Z

Day Range

1.782.04
LowHigh

52 Week Range

1.0613.20
LowHigh

Fundamentals

  • Previous Close 1.76
  • Market Cap11.91M
  • Volume350750
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.96881M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -17.54212M -32.12053M -50.25581M -26.08447M -130.24920M
Minority interest - - - - -
Net income -17.54212M -32.12053M -50.25581M -26.08447M -183.84700M
Selling general administrative 8.57M - 11.55M 9.77M 4.64M
Selling and marketing expenses - - - - -
Gross profit -0.22938M -0.22938M -0.26684M -0.23742M -0.22938M
Reconciled depreciation 0.23M - 0.23M 0.23M 0.23M
Ebit -17.20940M -32.17959M -45.95567M -23.92148M -138.03217M
Ebitda -16.98002M -31.95021M -45.68882M -23.68406M -137.80279M
Depreciation and amortization 0.23M 0.23M 0.27M 0.24M 0.23M
Non operating income net other - - - 3.33M -
Operating income -18.06620M -32.17959M -45.08045M -27.25298M -138.05414M
Other operating expenses 18.07M 32.18M 45.08M 27.25M 138.05M
Interest expense 0.33M 2.89M 4.30M 2.16M 0.56M
Tax provision - - - - -
Interest income 0.85M - 0.56M 0.04M 0.02M
Net interest income 0.52M - -3.73789M -2.11891M -0.53748M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.22938M 4.30M -3.28742M 0.56M
Total revenue 0.00000M - 0.00000M 0.00000M 0.00000M
Total operating expenses 17.84M 31.95M 45.08M 27.25M 138.05M
Cost of revenue 0.23M 0.23M 0.27M 0.24M 0.23M
Total other income expense net 0.52M 0.06M -5.17537M 1.17M 7.80M
Discontinued operations - - - - -
Net income from continuing ops -17.54212M - -50.25581M -26.08447M -130.24920M
Net income applicable to common shares - - -50.25581M -26.08447M -183.84752M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 21.56M 25.21M 35.10M 20.11M 6.05M
Intangible assets 0.18M 0.41M 0.64M 0.87M 1.10M
Earning assets - - - - -
Other current assets 1.05M 0.20M 0.10M 0.14M 0.09M
Total liab 2.55M 9.70M 19.76M 16.44M 1.00M
Total stockholder equity 19.01M 15.51M 15.34M 3.67M 5.05M
Deferred long term liab - - - - -
Other current liab 2.20M 0.00377M 5.34M 4.13M 1.00M
Common stock 0.00748M 0.00623M 0.00364M 0.00250M 0.00223M
Capital stock 0.00748M - 0.00364M 0.00250M 0.00223M
Retained earnings -352.14425M -334.23266M -301.22571M -250.96989M -224.88542M
Other liab - - - 0.05M -
Good will 0.35M 0.35M 0.35M 0.35M 0.35M
Other assets - - - 0.00456M -
Cash 17.54M 23.84M 19.46M 18.64M 4.51M
Cash and equivalents - - - - -
Total current liabilities 2.27M 9.35M 14.49M 4.17M 1.00M
Current deferred revenue - -3.58691M - - -
Net debt -17.19465M -17.73235M -5.04113M -6.37673M -4.51164M
Short term debt 0.07M 5.76M 9.15M 0.04M -
Short long term debt - - 9.11M - -
Short long term debt total 0.35M 6.11M 14.42M 12.26M -
Other stockholder equity 371.15M 349.73M 316.39M 254.64M 229.93M
Property plant equipment - - 0.08M 0.12M -
Total current assets 20.70M 24.05M 34.04M 18.78M 4.61M
Long term investments - - - - -
Net tangible assets - - 14.36M 2.46M 3.61M
Short term investments - - 14.48M - -
Net receivables 2.10M - - - -
Long term debt - - 5.23M 12.14M -
Inventory - - - - -
Accounts payable 2.20M 3.59M 3.48M 2.44M 1.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M 0.00000M 0.18M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00250M 0.00223M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -250.96989M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M - - 0.00456M -
Deferred long term asset charges - - - - -
Non current assets total 0.86M 1.16M 1.06M 1.33M 1.44M
Capital lease obligations 0.35M - 0.09M 0.13M -
Long term debt total - - - 12.14M -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M - -14.30114M -14.30114M -14.30114M
Change to liabilities - - 1.03M 2.80M -0.26283M
Total cashflows from investing activities - - -14.30114M -14.30114M -14.30114M
Net borrowings -5.85000M - - 14.61M -1.38582M
Total cash from financing activities 12.73M 17.80M 55.37M 33.12M 14.93M
Change to operating activities - - -1.30389M 1.30M 0.28M
Net income -17.54212M -32.12053M -50.25581M -26.08447M -130.24920M
Change in cash -6.29925M 4.38M 0.82M 14.13M 4.47M
Begin period cash flow 23.84M 19.46M 18.64M 4.51M 0.04M
End period cash flow 17.54M 23.84M 19.46M 18.64M 4.51M
Total cash from operating activities -19.02520M -27.94502M -40.25288M -18.99085M -10.45305M
Issuance of capital stock 15.67M - 55.37M 18.51M 15.63M
Depreciation 0.23M 0.23M 0.23M 0.23M 0.23M
Other cashflows from investing activities - - - - -
Dividends paid 369465.00M 0.89M - - 53.60M
Change to inventory - - - - -
Change to account receivables -2.10405M - - - -
Sale purchase of stock - - - 18.51M -
Other cashflows from financing activities 2.90M 14.53M 0.00224M 18.51M 0.69M
Change to netincome - - 9.87M 2.52M 119.55M
Capital expenditures 0.00001M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - 1.44M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 14.13M -
Change in working capital -4.39649M -0.08684M -0.27044M 2.75M 0.02M
Stock based compensation 2.47M 4.66M 6.38M 6.19M 3.02M
Other non cash items 0.21M -0.62714M 1037.12M -2.08062M 124.87M
Free cash flow -19.02520M -27.94502M -40.25288M -18.99085M -10.45305M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BIVI
Biovie Inc		 0.16 9.09% 1.92 - - - 0.62 -11.6556
NVO
Novo Nordisk A/S		 2.50 5.78% 45.69 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.55 1.23% 457.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -1.76 0.29% 608.18 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Biovie Inc

680 W. Nye Lane, Carson City, NV, United States, 89703

Key Executives

Name Title Year Born
Mr. Cuong Viet Do M.B.A., MBA Pres, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corp. Sec. 1955
Dr. Joseph M. Palumbo M.D. Chief Medical Officer 1960
Dr. Penelope Markham Ph.D. Exec. VP of Liver Disease R&D 1966
Ms. Denise Smith Sr. VP of Manufacturing & Devel. NA
Dr. Christopher L. Reading Ph.D. Exec. VP of Neuroscience R&D 1948
Mr. Clarence N. Ahlem Exec. VP of Neuroscience Product Devel. 1955
Ms. Sarah Overton Hoit Chief Social Impact Officer 1967
Mr. Cuong Viet Do M.B.A. President, CEO & Director 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corporate Secretary 1955

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.